Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q2- Text added to 2022 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
albumin, ALP, ALT, AST, baseline, Bilirubin, biochemical, carcinoma, case, Center, chemotherapy, committed, commonly, count, decompensated, deemed, demonstrated, demonstrating, dose, dosed, durable, EACRI, Earle, encouraging, fall, fixed, gastrointestinal, GGT, head, hematological, hemoglobin, HNSCC, immunologic, inflammation, INR, Institute, Keytruda, melanoma, metastatic, monotherapy, neck, numerical, placebo, population, Portland, ratio, recurrent, relevant, repeated, score, sixteen, spleen, stable, statistically, suggest, suggesting, tolerability, toxicity, transfusion, unrelated, unresectable, volume, white
Valuein 2022 Q2 filing- Value in 2022 Q3 filing
Original filings
Filing view